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IL-1b is amajor regulator of islet inflammation in type 2 diabetes. Several factors contribute to the induction of
islet-derived IL-1b, including glucose, free fatty acids, and leptin. A recent report in Nature Immunology
(Masters et al., 2010) identifies amyloid polypeptide as an additional enhancer of IL-1b production.Increasing evidence suggests that an
inflammatory process promotes islet
dysfunction in type 2 diabetes (Donath
et al., 2009). Indeed, islets of patients
with type 2 diabetes are characterized
by the presence of cytokines, NF-kB acti-
vation, immune cells, b cell apoptosis,
amyloid deposits, and fibrosis. This insuli-
tis is due to a pathological activation of the
innate immune system and governed by
IL-1 signaling. Supporting the critical role
of IL-1b, specific blockade of IL-1 activity
reduces the release of numerous inflam-
matory cytokines and chemokines from
islets exposed to metabolic stress,
thereby decreasing islet inflammation,
improving insulin secretion and glycae-
mia. Indeed, several clinical studies have
shown that targeting IL-b has the potential
to improve not only glycated hemoglobin
levels in patients with type 2 diabetes
but also to increase insulin production
(Larsen et al., 2007). These proof-of-
concept studies support a causal role for
IL-1 driven islet inflammation in the patho-
genesis of the disease.
Unraveling the underlying mechanism
of IL-1b activation in type 2 diabetes, in
their recent study in Nature Immunology,
Masters et al. (2010) discovered that
human islet amyloid polypeptide induces
IL-1b in bone-marrow-derived macro-
phages. This involves activation of the
NALP3 (also known as NLPR3) inflamma-
some resulting in caspase 1 activation
and subsequent processing of proIL-1b
and release of mature IL-1b. In a broader
context, metabolic disturbances consis-
tently appear to activate the IL-1 system
via the NALP3 inflammasome, for ex-
ample in amyloid deposits and hypergly-
caemia in pancreatic islets, in uric acid
crystals in the joint and cholesterol in
blood vessels (Dinarello, 2009; Duewellet al., 2010; Maedler et al., 2002; Martinon
et al., 2006; Masters et al., 2010;
Zhou et al., 2010). In the context of dia-
betes, high glucose concentrations
induce the dissociation of thioredoxin-in-
teracting protein from thioredoxin under
the influence of reactive oxygen species,
allowing binding to the NALP3 inflamma-
some and subsequent activation of cas-
pase 1.
While the ability of human amyloid
polypeptide to induce IL-1b in vitro in
bone-marrow-derived immune cells is
convincingly demonstrated in this study
(Masters et al., 2010), it is not clear
whether this mechanism results in b cell
failure. Mice transgenic for the expression
of human amyloid polypeptide (hIAPP
mouse) and fed a high-fat diet display
increased islet IL-1b staining, but whether
this increase in IL-1b is linked to diabetes
is not certain. Treatment of the hIAPP
mouse with an IL-1 antagonist followed
by measurements of glucose metabolism
and insulin levels will address the question
of whether IL-1b in the hIAPP mouse is
causative or merely an artifact of islets im-
munostaining due to the presence of
sticky fibrillar structures. Another point to
be clarified is the role of glucose. Glucose
has been repetitively shown to induce islet
derived IL-1b (Maedler et al., 2002; Zhou
et al., 2010)—an effect not reported in
this study since they only tested bone-
marrow-derived macrophages, which are
different from b cells in their ability to
sense changes in glucose levels.
Originally, the role of IL-1b in type 2 dia-
betes emerged in the context of glucose
toxicity in islets (Maedler et al., 2002).
Later, leptin and free fatty acids, both
elevated during the progression of
diabetes, were identified as additional
initiators of insulitis, via elevated IL-1bCell Metabolism 12,production (Boni-Schnetzler et al., 2009;
Maedler et al., 2004). Therefore, it was
proposed that excess nutrients initiated
islet inflammation directly or indirectly via
adipose tissue signals. However, excess
circulating nutrients and adipokines may
not be the only culprit, and amyloid, a hall-
mark of pancreatic islets from humans
with type 2 diabetes, is a valid suspect
(Masters et al., 2010). However, amyloid
deposition requires prolonged high-fat
feeding in the hIAPP mouse (1 year in the
paper of Masters et al. [2010]), while the
first signs of islet inflammation are
apparent after 8 weeks (Ehses et al.,
2007), indicating that this may be a late
event in the induction of islet inflammation
(Figure 1).
This study may have clinical relevance
for diabetes treatment. IL-1 antagonism
is already widely tested in patients with
type 2 diabetes (Larsen et al., 2007).
However, the optimal treatment modality
in this novel therapeutic approach re-
mains to be clarified. One open question
is the optimal treatment duration—i.e.,
short-term treatment versus continuous
dosing. That IL-1b induces itself in b cells
and thereby may induce a vicious cycle
favors a short-term treatment aiming at
blocking this vicious cycle. Another
question relates to the ideal time point
of intervention—i.e., treatment at early
versus late stages of the disease. Intui-
tively, one would argue in favor of IL-1
antagonism at early stages, when the
function of a larger mass of b cells can
be improved. However, accumulation of
amyloid deposits increases with time.
Therefore, blocking IL-1 activity may still
be effective at later stages of the
disease.
Although the precise role of amyloid-
induced IL-1b in islets remains to beNovember 3, 2010 ª2010 Elsevier Inc. 427
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Figure 1. Activation of IL-1b in Islets of Patients with Type 2 Diabetes
Glucose, free fatty acids (FFA), and adipokine (leptin) promote b cell production of IL-1b. In turn, IL-1b
induces the production and release of a wide panel of cytokines and chemokines, which recruit macro-
phages. Human islet polypeptide will then activate the macrophage NALP3 inflammasome, enhancing
IL-1b production. IL-1b will also induce itself initiating a vicious cycle.
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Previewsdetermined, its ability to activate the
NALP3 inflammasome adds further evi-
dence for a final effector pathway com-
mon to numerous islet stressors during
type 2 diabetes.428 Cell Metabolism 12, November 3, 2010 ªREFERENCES
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Glycogen metabolism serves as a critical regulator of energy storage and maintenance of blood glucose
levels in a physiological range. In this issue of Cell Metabolism, Bouskila et al. (2010) unexpectedly find
that skeletal muscle glycogen accumulation is principally controlled by the allosteric activation of glycogen
synthase, opening new avenues for investigation.Glycogen is the storage form of carbohy-
drate for virtually every organism from
yeast to mammals. In the 1850s, Claude
Bernard identified a starch-like substancein tissues and called it ‘‘glycogen,’’ or
‘‘sugar former.’’ Since its identification,
research into the regulation of glycogen
metabolism has led to fundamentaldiscoveries in biochemistry that are rele-
vant to nearly every biological system.
The Nobel Laureate Earl Sutherland iden-
tified cAMP as the first secondmessenger
